JP4205861B2 - 強化ワクチン - Google Patents

強化ワクチン Download PDF

Info

Publication number
JP4205861B2
JP4205861B2 JP2000579167A JP2000579167A JP4205861B2 JP 4205861 B2 JP4205861 B2 JP 4205861B2 JP 2000579167 A JP2000579167 A JP 2000579167A JP 2000579167 A JP2000579167 A JP 2000579167A JP 4205861 B2 JP4205861 B2 JP 4205861B2
Authority
JP
Japan
Prior art keywords
ige
polypeptide
domain
self
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2000579167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531064A (ja
JP2002531064A5 (enExample
Inventor
ヘルマン，ラース，ティー．
Original Assignee
レジステンシア ファーマシューティカルズ アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レジステンシア ファーマシューティカルズ アーベー filed Critical レジステンシア ファーマシューティカルズ アーベー
Publication of JP2002531064A publication Critical patent/JP2002531064A/ja
Publication of JP2002531064A5 publication Critical patent/JP2002531064A5/ja
Application granted granted Critical
Publication of JP4205861B2 publication Critical patent/JP4205861B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000579167A 1998-11-02 1999-10-21 強化ワクチン Expired - Fee Related JP4205861B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10665298P 1998-11-02 1998-11-02
US60/106,652 1998-11-02
US09/401,636 US6913749B2 (en) 1998-11-02 1999-09-22 Immunogenic polypeptides for inducing anti-self IgE responses
US09/401,636 1999-09-22
PCT/SE1999/001896 WO2000025722A2 (en) 1998-11-02 1999-10-21 ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005258648A Division JP4188353B2 (ja) 1998-11-02 2005-09-07 強化ワクチン

Publications (3)

Publication Number Publication Date
JP2002531064A JP2002531064A (ja) 2002-09-24
JP2002531064A5 JP2002531064A5 (enExample) 2005-12-22
JP4205861B2 true JP4205861B2 (ja) 2009-01-07

Family

ID=26803871

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000579167A Expired - Fee Related JP4205861B2 (ja) 1998-11-02 1999-10-21 強化ワクチン
JP2005258648A Expired - Fee Related JP4188353B2 (ja) 1998-11-02 2005-09-07 強化ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005258648A Expired - Fee Related JP4188353B2 (ja) 1998-11-02 2005-09-07 強化ワクチン

Country Status (17)

Country Link
US (3) US6913749B2 (enExample)
EP (1) EP1135158B1 (enExample)
JP (2) JP4205861B2 (enExample)
KR (1) KR100559918B1 (enExample)
AT (1) ATE314087T1 (enExample)
AU (1) AU771889B2 (enExample)
CA (1) CA2348756A1 (enExample)
DE (1) DE69929240T2 (enExample)
DK (1) DK1135158T3 (enExample)
ES (1) ES2255325T3 (enExample)
HU (1) HUP0105392A3 (enExample)
IL (1) IL142582A0 (enExample)
NO (1) NO20012135L (enExample)
NZ (1) NZ511079A (enExample)
PL (1) PL348611A1 (enExample)
PT (1) PT1135158E (enExample)
WO (1) WO2000025722A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7658101A (en) * 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
EP2361635A3 (en) * 2000-08-30 2011-09-14 Pfizer Products Inc. Anti IgE vaccines
JP2004508028A (ja) * 2000-09-06 2004-03-18 ファーメクサ　エイ／エス ＩｇＥをダウン−レギュレートさせる方法
CA2698079C (en) 2001-02-20 2015-01-13 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
US20040071671A1 (en) 2001-02-20 2004-04-15 Leturcq Didier J. Cell therapy method for the treatment of tumors
ES2329453T3 (es) * 2001-05-15 2009-11-26 Ortho Mcneil Janssen Pharm Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas.
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
CA2486464A1 (en) * 2002-05-21 2003-11-27 Resistentia Pharmaceuticals Ab Chimeric ige polypeptides and host cells
CA2497660A1 (en) * 2002-09-05 2004-03-18 Resistentia Pharmaceuticals Ab Allergy vaccines
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2010067286A2 (en) 2008-12-09 2010-06-17 Pfizer Vaccines Llc IgE CH3 PEPTIDE VACCINE
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
EP2862873B1 (en) 2012-06-18 2020-04-29 Nippon Zenyaku Kogyo Co., Ltd. IgE PEPTIDE VACCINE
SG11201806427WA (en) 2016-02-16 2018-08-30 Regeneron Pharma Non-human animals having a mutant kynureninase gene
EP4582442A3 (en) 2019-06-24 2025-10-29 Universität Stuttgart Tnfr2 agonists with improved stability

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767842A (en) 1973-05-07 1988-08-30 The Ohio State University Antigenic modification of polypeptides
US5698201A (en) 1973-05-07 1997-12-16 The Ohio State University Method for treatment of antigenically modified polypeptides
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4483793A (en) 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
US4782137A (en) 1984-01-24 1988-11-01 Immunex Corporation Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5175385A (en) 1987-09-03 1992-12-29 Ohio University/Edison Animal Biotechnolgy Center Virus-resistant transgenic mice
GB8727045D0 (en) 1987-11-19 1987-12-23 Research Corp Ltd Immunoglobulin e competitor
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
DE122006000007I2 (de) 1987-12-31 2008-03-27 Tanox Inc -tragenden b-lymphocyten befinden.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8910263D0 (en) 1989-05-04 1989-06-21 Ciba Geigy Ag Monoclonal antibodies specific for an immunoglobulin isotype
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5955076A (en) 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
US5733553A (en) 1989-09-29 1998-03-31 Talwar; Gursaran Prasad Recombinant birth control vaccine
AU645783B2 (en) 1990-01-23 1994-01-27 Tanox Biosystems, Inc. Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor
EP0605410B1 (en) 1990-05-25 1995-08-16 Peptide Therapeutics Limited Immunodiagnostic assay for rheumatoid arthritis
US5196197A (en) 1990-08-29 1993-03-23 National Institute Of Immunology Reversible fertility control for prevention of pregnancy in females
FI932477L (fi) * 1990-12-13 1993-06-11 Immunex Corp Receptorer foer leukemi-inhiberande faktor
SE9102808L (sv) 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
US5837686A (en) 1991-11-25 1998-11-17 Peptide Therapeutics Limited Peptides and antibodies for treatment of rheumatoid arthritis
EP0662085A1 (en) 1992-09-01 1995-07-12 International Centre for Genetic Engineering and Biotechnology Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum
WO1994008601A1 (en) 1992-10-14 1994-04-28 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates
US5762931A (en) 1992-12-31 1998-06-09 National Institute Of Immunology Anti-cancer utility of HCG vaccines
US5532142A (en) * 1993-02-12 1996-07-02 Board Of Regents, The University Of Texas System Method of isolation and purification of fusion polypeptides
US5552537A (en) * 1993-03-24 1996-09-03 The Regents Of The University Of California IgE isoforms and methods of use
US5501855A (en) 1993-09-02 1996-03-26 Talwar; Gursaran P. Neem oil as a male contraceptive
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5874085A (en) 1993-11-10 1999-02-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Vaccine for enhanced production of IgA antibodies
FR2715304B1 (fr) 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
CN1146772A (zh) 1994-03-28 1997-04-02 美国联合生物医学公司 用于治疗过敏反应的合成肽免疫原
US5651981A (en) * 1994-03-29 1997-07-29 Northwestern University Cationic phospholipids for transfection
CA2203165A1 (en) 1994-10-25 1996-05-02 United Biomedical, Inc. Synthetic ige membrane anchor peptide immunogens for the treatment of allergy
GB9422294D0 (en) 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
JPH08333390A (ja) 1995-04-07 1996-12-17 Hoechst Japan Ltd ペプチド及びそれからなる自己免疫疾患治療剤
AU716716B2 (en) 1995-07-17 2000-03-02 Medivir Uk Ltd Cysteine protease inhibitors for use in treatment of IgE mediated allergic diseases
ZA966075B (en) 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
AU719609B2 (en) 1996-03-01 2000-05-11 Novartis Ag Peptide immunogens for vaccination against and treatment of allergy
CA2262001C (en) 1996-08-05 2003-05-20 President And Fellows Of Harvard College Mhc binding peptide oligomers and methods of use
ZA983148B (en) 1997-04-15 1999-10-15 Ferring Farma Lab Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA.
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
AU2674299A (en) 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
US6299875B1 (en) 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
DE69939836D1 (de) 1998-11-30 2008-12-11 Cytos Biotechnology Ag Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
EA200101125A1 (ru) 1999-04-23 2002-04-25 Фармекса А/С Способ понижающей регуляции активности il5
AU7658101A (en) 2000-07-28 2002-02-13 Cytos Biotechnology Ag Compositions for inducing self-specific anti-ige antibodies and uses thereof
JP2004508028A (ja) 2000-09-06 2004-03-18 ファーメクサ　エイ／エス ＩｇＥをダウン−レギュレートさせる方法
US20040198961A1 (en) 2001-06-15 2004-10-07 Ling-Ling An Fce fusion proteins for treatment of allergy and asthma

Also Published As

Publication number Publication date
JP2002531064A (ja) 2002-09-24
JP4188353B2 (ja) 2008-11-26
ATE314087T1 (de) 2006-01-15
US7459158B2 (en) 2008-12-02
IL142582A0 (en) 2002-03-10
HUP0105392A2 (hu) 2002-04-29
DE69929240D1 (de) 2006-02-02
DE69929240T2 (de) 2006-08-31
KR100559918B1 (ko) 2006-03-13
HUP0105392A3 (en) 2008-04-28
PL348611A1 (en) 2002-06-03
AU2008100A (en) 2000-05-22
KR20010089364A (ko) 2001-10-06
NZ511079A (en) 2003-08-29
WO2000025722A2 (en) 2000-05-11
US20030031663A1 (en) 2003-02-13
EP1135158B1 (en) 2005-12-28
HK1042844A1 (en) 2002-08-30
ES2255325T3 (es) 2006-06-16
WO2000025722A3 (en) 2000-10-12
NO20012135D0 (no) 2001-04-30
US6913749B2 (en) 2005-07-05
CA2348756A1 (en) 2000-05-11
PT1135158E (pt) 2006-05-31
DK1135158T3 (da) 2006-05-15
EP1135158A2 (en) 2001-09-26
NO20012135L (no) 2001-06-25
US20010038843A1 (en) 2001-11-08
AU771889B2 (en) 2004-04-08
US20040076625A1 (en) 2004-04-22
JP2006068015A (ja) 2006-03-16

Similar Documents

Publication Publication Date Title
JP4205861B2 (ja) 強化ワクチン
ES2144424T5 (es) Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige.
DE60025832T2 (de) Mehrere zytokin-antikörper komplexen
JPH03501927A (ja) ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基
JP2003534821A (ja) Ｔ細胞レセプター融合体および結合体ならびにそれらの使用方法
AU2018383708B2 (en) Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis
JPH09509316A (ja) 寛容原性融合タンパク質による寛容性の誘発
US20100021486A1 (en) Tslp vaccine for the treatment of th2 mediated inflammatory conditions
RU2214279C2 (ru) Усовершенствованные вакцины
JP7649923B2 (ja) ＧＰＣ３標的化抗体インターフェロンα融合タンパク質及びその使用
WO2000023477A2 (en) Immunoglobulin variants
EP1621209A2 (en) Vaccines based on domains of chimeric immunoglobulin E peptides
JP2000502995A (ja) Ｂリンパ球による抗体放出を刺激する組成物および方法
MXPA01004372A (en) Enhanced vaccines
HK1042844B (en) Enhanced vaccines based on chimeric immunoglobulin e peptides
JPH06503956A (ja) 腫瘍細胞に対する標的決定ＩｇＥエフェクター細胞
KR20200115522A (ko) IgE 매개된 알레르기성 질환의 치료를 위해 막-결합된 IgE를 표적화하는 펩타이드 면역원 및 이의 제형물
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta
MXPA97004173A (en) Designated citoquina lce

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040816

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20040915

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20041026

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20040930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20050510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20051013

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20051115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20060106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080807

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20081017

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111024

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees